{"name":"ProQR Therapeutics","slug":"proqr","ticker":"PRQR","exchange":"NASDAQ","domain":"proqr.com","description":"ProQR Therapeutics N.V., a clinical-stage biotechnology company, focuses on the discovery and development of novel therapeutic medicines. The company develops an RNA editing platform through its Axiomer RNA editing technology for genetic disorders with unmet needs. Its lead product candidate, AX-0810, targets na-taurocholate cotransporting polypeptide (NTCP) for the treatment of cholestatic diseases. The company also develops AX-2402, which targets methyl CpG binding protein 2 mutations for Rett syndrome; AX-2911, which targets PNPLA3 for metabolic dysfunction-associated steatohepatitis; and AX-1412, which targets the B4GALT1 gene for cardiovascular diseases. It has a research and collaboration agreement with Eli Lilly and Company for the discovery, development, and commercialization of potential new medicines for genetic disorders in the liver and nervous system. The company was incorporated in 2012 and is headquartered in Leiden, the Netherlands.","hq":"Leiden, Netherlands","founded":0,"employees":"186","ceo":"Daniel de Boer","sector":"Clinical-Stage RNA Therapeutics","stockPrice":1.67,"stockChange":-0.03,"stockChangePercent":-1.76,"marketCap":"$206M","metrics":{"revenue":15931549.504199998,"revenueGrowth":-57.1,"grossMargin":100,"rdSpend":0,"netIncome":-53133977.84639999,"cash":94717903.52639998,"dividendYield":0,"peRatio":-2.6,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"QR-010","genericName":"QR-010","slug":"qr-010","indication":"Other","status":"phase_1"}]}],"pipeline":[{"name":"QR-010","genericName":"QR-010","slug":"qr-010","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""}],"recentEvents":[{"date":"2024-02-27","type":"earnings","headline":"ProQR Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results","summary":"ProQR Therapeutics reported its fourth quarter and full year 2023 financial results, with a net loss of $43.1 million for the year.","drugName":"","sentiment":"neutral"},{"date":"2023-11-14","type":"trial","headline":"ProQR Therapeutics Announces Positive Topline Results from Phase 1/2 Clinical Trial of QR-421a in Patients with Leber Congenital Amaurosis 10","summary":"ProQR Therapeutics announced positive topline results from its Phase 1/2 clinical trial of QR-421a in patients with Leber congenital amaurosis 10.","drugName":"","sentiment":"positive"},{"date":"2023-08-01","type":"deal","headline":"ProQR Therapeutics Enters into Collaboration and License Agreement with Sanofi","summary":"ProQR Therapeutics entered into a collaboration and license agreement with Sanofi to develop and commercialize QR-421a for the treatment of Leber congenital amaurosis 10.","drugName":"","sentiment":"positive"}],"realNews":[{"date":"2026-04-08","type":"earnings","source":"SEC EDGAR","summary":"6-K filed with SEC: FORM 6-K","headline":"6-K Filing","sentiment":"neutral"},{"date":"2026-03-25","type":"earnings","source":"SEC EDGAR","summary":"6-K filed with SEC: FORM 6-K","headline":"6-K Filing","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2026-03-13","type":"earnings","source":"simplywall.st","summary":"ProQR Therapeutics Q4 Net Loss Of €8.9 Million Reinforces Profitability Concerns - simplywall.st","headline":"ProQR Therapeutics Q4 Net Loss Of €8.9 Million Reinforces Profitability Concerns","sentiment":"neutral"},{"date":"2026-03-12","type":"earnings","source":"SEC EDGAR","summary":"20-F filed with SEC: 20-F","headline":"Annual Report (20-F) Filed","sentiment":"neutral"},{"date":"2026-03-12","type":"earnings","source":"SEC EDGAR","summary":"6-K filed with SEC: FORM 6-K","headline":"6-K Filing","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMitAFBVV95cUxNZFhobEYyVlpka3FaNFRGSUNBOGJUUnVmS245NW9PYXN1aWlKY01jUVdqZUN3UW1PMDVEbktQcDZORVktYktUcVpwRnhzb1dzLURvRlpUSjQ0RnF0bmIzZ0doMUNTYndTVkVaSE45ZFlMeTZKblYxdnBtaUc1VTVPbVkxSkI1c29LRzFVcGEtVjhHNmJOWkJZaXc3QnpnVGZKX29VSmppZEVtZF9wMkZrdDNINy0?oc=5","date":"2026-03-09","type":"pipeline","source":"Benzinga","summary":"12 Health Care Stocks Moving In Monday's Pre-Market Session - Benzinga","headline":"12 Health Care Stocks Moving In Monday's Pre-Market Session","sentiment":"neutral"},{"date":"2026-02-09","type":"earnings","source":"SEC EDGAR","summary":"6-K filed with SEC: FORM 6-K","headline":"6-K Filing","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi5wFBVV95cUxPTVc0QW42c0ZPZzR0YmtkcXBfb2oyYkJCQmkwQXd6ODJfVWVBQkU4ODUyaEFldkpGRDJvRmdiY3pobnV6WkpyVTBzTzI0YUxvclQyc1dERWRvZkRwYm1CYks5RnBwTi1nUktWT0JTdm10cV80VXQyVkdsbTFXQXVQTlpzV2dmeUppcVdabE9ZWlJ4Y19faVlTZnQ1bm5DcU9GeGwyaWJQOXUwU1JHT0VmZkxrTE44eG5ZNFFvTjA0VzJETmgxRkNlRkpEcHBGV3VvdnVwZlNkVHFWQWp3a25KM1JLQ1JQMm_SAewBQVVfeXFMTUxvNVRYZFI4aGhzbVhHV2tYV2ZWZXREWEl2WE5oR3UwSmdzU2p1MUJqVFc5dWwtU3dKdi1DZ21wOXUwdW5TWVBJanp1czk5ZVZyNVVJSUlXSGZZZkxOdXNmS3Y3NkJ0azFQSV9Od3pYdlJwWldTZHdLUFNnamRZWWNkb0I2dlpLOXhsODlsSXZueTBQdnF6NTZLakFZVkRuU2VyTzF3bEc4Ykg5b29PeVpRN0JVOHlubkx6eVFXdHF2VEpDMGRtbWdLM01PYW9FOV9EV0JxcHVPbldPOGJzWlZ0Ym1SUGgwS1RMVVM?oc=5","date":"2026-01-13","type":"pipeline","source":"simplywall.st","summary":"Why Investors Shouldn't Be Surprised By ProQR Therapeutics N.V.'s (NASDAQ:PRQR) 28% Share Price Plunge - simplywall.st","headline":"Why Investors Shouldn't Be Surprised By ProQR Therapeutics N.V.'s (NASDAQ:PRQR) 28% Share Price Plunge","sentiment":"neutral"},{"date":"2026-01-08","type":"earnings","source":"SEC EDGAR","summary":"6-K filed with SEC: FORM 6-K","headline":"6-K Filing","sentiment":"neutral"},{"date":"2025-11-06","type":"earnings","source":"SEC EDGAR","summary":"6-K filed with SEC: 6-K","headline":"6-K Filing","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2025-11-05","type":"pipeline","source":"simplywall.st","summary":"Is ProQR Therapeutics (NASDAQ:PRQR) Using Debt Sensibly? - simplywall.st","headline":"Is ProQR Therapeutics (NASDAQ:PRQR) Using Debt Sensibly?","sentiment":"neutral"},{"date":"2025-11-03","type":"earnings","source":"SEC EDGAR","summary":"6-K filed with SEC: FORM 6-K","headline":"6-K Filing","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2025-05-27","type":"pipeline","source":"simplywall.st","summary":"Here's Why ProQR Therapeutics N.V.'s (NASDAQ:PRQR) CEO May Deserve A Raise - simplywall.st","headline":"Here's Why ProQR Therapeutics N.V.'s (NASDAQ:PRQR) CEO May Deserve A Raise","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi7AFBVV95cUxPZlktdGx2cjV6QUZDTXBjZEpJWjlGTGFRVFoweWZTdEVEZ2MzTlJXTGRvQmtxQzYwWktWZXpaWmVKOWNudTdzamhkMWlFa0dzUTVNVGx2TEpvcHAybndadXlVam1PaVA0OHZHUjloWFBqQ1U4ejBObmZveEw1NlJMUnFIVGRMME95TnlhU2NUUWxYUlN3clpQT2xPNHEwTndRSS05Uk9xRmlmSmF4b2g4N1pJSm4zc21GSlVORkhWOHRzNG9JNDlHcGp2cmNBWWJ3Y1FSYnh1dS1LaXBIX1NiZnlISS11TkZDLW1MT9IB8gFBVV95cUxNWWJFQzNtbmw5N0hlQ244eS16NUhldjVRaHpNUzM1MGtobmxWeXhjZWprbWhyQlhwMzU2TGNFd0xmODJKeE4tMGhRVnlBcWsxdW9SOEVvOE1tdHBmR0NnbEtfY2xfOVphR0ZnZUtDMGpTNzB3UUtZLUlZNlJESVdMUXJ6VXI4R25qYm8yNWdUYVI4alhUbXRTNjQwZ1NnY05feHh3dE5sRVFJQkU0Rzl1SEZBdGlIT2xVOWhvYm5CUzdoajFLSC0zVExWUzE5M1NPYWNrYmc4ejhaRWVRWDE5VERvSUlDRHExZmpXVXdKUEJqdw?oc=5","date":"2025-05-09","type":"pipeline","source":"simplywall.st","summary":"New Forecasts: Here's What Analysts Think The Future Holds For ProQR Therapeutics N.V. (NASDAQ:PRQR) - simplywall.st","headline":"New Forecasts: Here's What Analysts Think The Future Holds For ProQR Therapeutics N.V. (NASDAQ:PRQR)","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMigAFBVV95cUxPc2RPRnJ3SVhhZTJtOGFnc1p5Z0FmMGRQNHVVR25BcGNDM2NHd1NtTFFWNkdqdEJlcGhKZ0tud3dtYWdMclR5Q2lCRXNnSEp1ekJRNHVaRFdMaUZRcDVKZXFZNE5BVmZCWk9MWktGVFVYQ0d1Nm9lSTdLSUg4VG40Vw?oc=5","date":"2020-05-02","type":"pipeline","source":"MarketBeat","summary":"Top ProQR Therapeutics (PRQR) Competitors 2026 - MarketBeat","headline":"Top ProQR Therapeutics (PRQR) Competitors 2026","sentiment":"neutral"}],"patents":[],"drugCount":1,"phaseCounts":{"phase_1":1},"enrichmentLevel":3,"visitCount":1,"keyCompetitors":["Vertex Pharmaceuticals","Biogen","Pfizer"],"therapeuticFocus":["Cystic Fibrosis","Leber Congenital Amaurosis","Huntington's Disease"],"financials":{"source":"sec_edgar+yahoo","revenue":18579604.5468,"revenuePeriod":"2025-12-31","revenueHistory":[{"period":"2025-12-31","value":18579604.5468},{"period":"2024-12-31","value":22082699.858999997},{"period":"2023-12-31","value":7608923.929199999},{"period":"2022-12-31","value":4198107.5532}],"grossProfit":null,"grossProfitHistory":[],"rdSpend":52252071.557399996,"rdSpendHistory":[{"period":"2025-12-31","value":52252071.557399996},{"period":"2024-12-31","value":42467000.05679999},{"period":"2023-12-31","value":29375071.9944},{"period":"2022-12-31","value":59417122.1226}],"sgaSpend":17591402.268,"operatingIncome":-50748742.5588,"operatingIncomeHistory":[{"period":"2025-12-31","value":-50748742.5588},{"period":"2024-12-31","value":-35593971.441599995},{"period":"2023-12-31","value":-40637774.562},{"period":"2022-12-31","value":-76111432.9602}],"netIncome":-49274615.7552,"netIncomeHistory":[{"period":"2025-12-31","value":-49274615.7552},{"period":"2024-12-31","value":-32429621.591399997},{"period":"2023-12-31","value":-32845460.848199997},{"period":"2022-12-31","value":-75252888.42719999}],"eps":-0.32,"epsHistory":[{"period":"2024-12-31","value":-0.32},{"period":"2023-12-31","value":-0.35},{"period":"2022-12-31","value":-0.9},{"period":"2021-12-31","value":-0.96}],"cash":107946497.8614,"cashHistory":[{"period":"2025-12-31","value":107946497.8614},{"period":"2024-12-31","value":174521662.0224},{"period":"2023-12-31","value":138914841.61499998},{"period":"2022-12-31","value":110705521.24499999}],"totalAssets":131708907.9768,"totalLiabilities":74035740.93959999,"totalDebt":18647353.6392,"equity":57673167.0372,"operatingCashflow":-61664523.04979999,"operatingCashflowHistory":[{"period":"2025-12-31","value":-61664523.04979999},{"period":"2024-12-31","value":-42510219.3054},{"period":"2023-12-31","value":25169955.914399996},{"period":"2022-12-31","value":-80023359.0024}],"capex":-1191449.5559999999,"capexHistory":[{"period":"2025-12-31","value":-1191449.5559999999},{"period":"2024-12-31","value":-1656348.5003999998},{"period":"2023-12-31","value":-1601448.3738},{"period":"2022-12-31","value":-827006.1623999999}],"freeCashflow":-62855972.605799995,"dividendsPaid":null,"buybacks":null,"employees":186,"segmentRevenue":[],"geographicRevenue":[],"quarterly":{"income":[{"sga":4545029.629799999,"ebit":-8044620.678599999,"ebitda":-7251489.062399999,"period":"2025-12-31","revenue":5475995.6064,"epsBasic":null,"netIncome":-10419343.175999999,"rdExpense":11589767.1516,"epsDiluted":null,"grossProfit":null,"operatingIncome":-10626094.716599999},{"sga":3643265.8482,"ebit":-13180702.735199999,"ebitda":-12396915.8214,"period":"2025-09-30","revenue":3366429.0396,"epsBasic":-0.1,"netIncome":-12855974.326799998,"rdExpense":12942412.824,"epsDiluted":-0.1,"grossProfit":null,"operatingIncome":-13180702.735199999},{"sga":5625510.844799999,"ebit":-14307907.462199999,"ebitda":-13519448.197199998,"period":"2025-06-30","revenue":4458591.132599999,"epsBasic":-0.12,"netIncome":-14226141.3162,"rdExpense":13325545.622399999,"epsDiluted":-0.12,"grossProfit":null,"operatingIncome":-14307907.462199999},{"sga":3777595.9451999995,"ebit":-12634037.644799998,"ebitda":-11842074.1164,"period":"2025-03-31","revenue":5278588.7682,"epsBasic":-0.1,"netIncome":-11773156.936199998,"rdExpense":14394345.959399998,"epsDiluted":-0.1,"grossProfit":null,"operatingIncome":-12634037.644799998},{"sga":4570727.5614,"ebit":-7583225.997599999,"ebitda":-6799439.083799999,"period":"2024-12-31","revenue":5030954.1546,"epsBasic":null,"netIncome":-10869056.978999998,"rdExpense":12394579.645799998,"epsDiluted":null,"grossProfit":null,"operatingIncome":-11775493.111799998},{"sga":null,"ebit":null,"ebitda":null,"period":"2024-09-30","revenue":null,"epsBasic":-0.1,"netIncome":null,"rdExpense":null,"epsDiluted":-0.1,"grossProfit":null,"operatingIncome":null}]},"ciks":null,"lastFiledAt":null},"yahoo":{"currentPrice":1.67,"previousClose":1.7,"fiftyTwoWeekHigh":3.1,"fiftyTwoWeekLow":1.33,"fiftyTwoWeekRange":"1.33 - 3.1","fiftyDayAverage":1.69,"twoHundredDayAverage":1.99,"beta":0,"enterpriseValue":132882583.90883519,"forwardPE":-2.6,"priceToBook":3.05,"priceToSales":12.9,"enterpriseToRevenue":8.34,"enterpriseToEbitda":-2.51,"pegRatio":0,"ebitda":-52985630.6958,"ebitdaMargin":0,"freeCashflow":-27058753.887,"operatingCashflow":-56229410.516399994,"totalDebt":18377525.3574,"debtToEquity":41.8,"currentRatio":2.48,"returnOnAssets":-23.1,"returnOnEquity":-78.1,"analystRating":"1.1 - Strong Buy","recommendationKey":"strong_buy","numberOfAnalysts":8,"targetMeanPrice":8.88,"targetHighPrice":14,"targetLowPrice":4,"dividendRate":0,"payoutRatio":0,"fiveYearAvgDividendYield":0,"exDividendDate":0,"insiderHeldPercent":17.7,"institutionHeldPercent":50.9,"sharesOutstanding":105361064,"floatShares":64346820,"sharesShort":844972,"shortRatio":0.97,"shortPercentOfFloat":0.8,"epsTrailing":-0.47,"epsForward":-0.64,"revenuePerShare":0.13,"bookValue":0.55,"officers":[{"age":42,"name":"Mr. Daniel Anton de Boer","title":"Founder, CEO & Executive Director"},{"age":61,"name":"Dr. Gerard  Platenburg Ph.D.","title":"Co-Founder, Chief Scientific Officer & Executive Director"},{"age":50,"name":"Mr. Dennis  Hom","title":"Chief Financial Officer"},{"age":41,"name":"Ms. Sheila  Sponselee","title":"Chief People & Operations Officer"},{"age":null,"name":"Ms. Sarah Cue Kiely","title":"Vice President of Investor Relations & Corporate Communications"},{"age":49,"name":"Dr. Cristina  Lopez Lopez M.D., Ph.D.","title":"Chief Medical Officer"},{"age":null,"name":"Ms. Sandra  van der Kolk","title":"Junior Financial Controller"}],"industry":"Biotechnology","irWebsite":"","website":"https://www.proqr.com","phone":"31 88 166 7000"}}